Introduction
============

Asthma is a heterogeneous disease with different clinical phenotypes.[@b1-jaa-10-131],[@b2-jaa-10-131] Each phenotype can demonstrate one or more molecular endotypes amenable to therapeutic intervention. While allergic asthma remains a common asthma phenotype, many conflicting results persist, specifically on the role of allergen sensitization in determining the severity and prognosis of severe asthma.[@b3-jaa-10-131] Among the various allergens, fungal sensitization is associated with increased asthma severity,[@b4-jaa-10-131]--[@b6-jaa-10-131] evidenced by increased hospital admissions for exacerbations and poorer lung function.[@b7-jaa-10-131],[@b8-jaa-10-131] The entity of severe asthma with fungal sensitization (SAFS) has, therefore, been coined, which is characterized by the presence of severe asthma, fungal sensitization and the exclusion of allergic bronchopulmonary aspergillosis (ABPA).[@b9-jaa-10-131] This proposed subtype of severe asthma is clinically recognized; however, data to support its true prevalence and treatment outcomes remain unclear.

Studies focused on fungal sensitization in asthmatics are heterogeneous and have, to date, included differing asthma severities, making their conclusions difficult to interpret, particularly in the context of severe asthma. Data remain lacking in patients with severe asthma, who, we hypothesize, would likely be most affected by documented fungal sensitization. Importantly, current literature is focused largely on the Caucasian population, with a consequent paucity of literature on allergen sensitization in the severe asthma population in Asia. This is critical because allergen sensitization in the east is likely to be different from other parts of the world due to complex interplay between genetics and environmental ethnogeography in determining an individual's sensitization state. We, therefore, studied the prevalence of sensitization including *Aspergillus* species and its association with asthma-related outcomes in a multiethnic South East Asian population with severe asthma.

Methods
=======

This was a cross-sectional study conducted at Singapore General Hospital. All recruited patients were at minimum receiving step 4 or 5 Global Initiative for Asthma (GINA) treatment, that is, they required a combination of medium to high-dose inhaled corticosteroids (\>250 μg equivalent of fluticasone) and long-acting beta agonists. Diagnosis of asthma was made on the basis of a history of episodic wheeze and dyspnea, clinical examination and supported by spirometry (reversibility of forced expiratory volume in 1 second \[FEV~1~\] of \>12% and 200 mL, or demonstration of bronchial hyper-responsiveness with a positive methacholine challenge test or FEV~1~ variability of \>15%). Demographic characteristics including age, ethnicity, gender, age of asthma onset, presence of allergic rhinitis, family history of asthma, smoking status and body mass index (BMI) were collated. Skin prick tests (SPTs) were performed with a comprehensive panel (Stallergenes, Antony, Hauts-de-Seine, France) that included the following extracts: house dust mites (HDM; *Blomia tropicalis* \[BT\], *Dermatophagoides pteronyssinus* \[DP\] and *Dermatophagoides farinae* \[DF\]), dog and cat dander, mixed feathers, cockroach and *Aspergillus* mix (*Aspergillus fumigatus*, *Aspergillus nidulans*, *Aspergillus niger*). The negative control was glycerin and the positive control histamine, both at 10 mg/mL. A positive response was defined as any allergen-induced wheal of 3 mm greater than the negative control, 15 minutes after application. Asthma control test scores were recorded at baseline. Spirometry was performed as per the American Thoracic Society/European Respiratory Society guidelines, using a Medgraphics (St Paul, MN, USA) spirometer. Indicators of uncontrolled asthma (defined as ≥2 steroid bursts required for asthma exacerbations in the past year, ≥1 asthma exacerbation requiring hospitalization in the past year, a history of near-fatal asthma, i.e., received mechanical ventilation for severe asthma exacerbation, or FEV~1~ \<80% predicted and FEV~1~/forced vital capacity \[FVC\] \<0.7 on pulmonary function testing) were determined by history and correlated with electronic health records and clinical investigations. Ethics approval from the Singhealth Institutional Review Board was obtained (CIRB: 2010/810/C) including written consent from the participants.

Statistical analysis
--------------------

Continuous variables are presented as mean ± standard deviation (SD) or median (interquartile range \[IQR\]), and comparisons between groups were performed using independent *t*-tests and the Mann--Whitney *U* test, respectively, for normal and non-normal data sets. Categorical variables are presented as numbers (percentages), and comparisons were performed using the Pearson's *χ*^2^ or the Fisher's exact test, where appropriate. Comparisons between three variables were performed using one-way analysis of variance and Kruskal--Wallis tests for normal and non-normal data sets, respectively. Multivariate logistical regression was performed to estimate adjusted odds ratios (ORs) for the associations between specific allergen sensitization and indicators of uncontrolled asthma, taking into account potential confounding factors (age, ethnicity, gender, BMI, smoking history and all other allergens). All data were assessed using Statistical Package for the Social Sciences (version 17.0; SPSS Inc., Chicago, IL, USA) for analysis, and *p* values \<0.05 were considered statistically significant.

Results
=======

Patient characteristics
-----------------------

Two hundred and six patients were included and their baseline characteristics are presented in [Table 1](#t1-jaa-10-131){ref-type="table"}. The cohort consisted of a broad ethnic distribution including 61.2% Chinese, 16.5% Malay, 14.1% Indian and 8.3% other ethnic groups. Patients were on treatment with a median of three (IQR: 2--3) controllers (controllers defined as inhaled corticosteroids, long-acting beta agonists, theophylline, leukotriene receptor antagonists, long-term systemic steroids, omalizumab or long-acting anticholinergics). All patients were on two or more controllers, with 91 (44.2%) patients on three controllers and 24 (11.6%) on four or more controllers. The median asthma control test score recorded at baseline was 18 (IQR: 15--21). Forty-five (21.8%) patients required ≥2 steroid bursts for asthma exacerbations in the past year, 35 (17.0%) patients had at least one hospitalization for asthma exacerbation in the past year, 11 (6.3%) patients had a history of near-fatal asthma and 69 (33.5%) patients had FEV~1~ \<80% predicted and FEV~1~/FVC \<0.7 on pulmonary function testing. Overall, 109 (53.9%) patients had one or more of the abovementioned indicators of uncontrolled asthma.

Prevalence of allergen sensitization
------------------------------------

One hundred and sixty-two (78.6%) patients had a positive SPT to one or more allergen extracts ([Figure 1](#f1-jaa-10-131){ref-type="fig"}). HDM sensitization was the most common: 70.4%, 70.9% and 69.4% of patients were sensitized to BT, DP and DF, respectively. The other sensitization profiles are: dog dander (32.0%), cat dander (33.0%), cockroach (23.3%), mixed feathers (11.2%) and *Aspergillus* mix (11.7%). Overall, patients were sensitized to a median of three allergens (IQR: 1--5), and 96 (46.6%) patients had sensitization to four or more allergens. Twelve patients in our study had requested for the removal of dog dander extract testing during SPT due to religious preference. These were taken to have a negative response on the SPT for dog dander for the purpose of analysis.

Determinants of uncontrolled asthma in a cohort of severe asthma
----------------------------------------------------------------

We compared the baseline characteristics and allergen sensitization profiles of severe asthma patients with and without indicators of uncontrolled asthma ([Table 2](#t2-jaa-10-131){ref-type="table"}). Patients with uncontrolled asthma had a higher rate of sensitization to *Aspergillus* (18.3% in uncontrolled asthma and 4.1% in controlled asthma, *p*=0.001). There were no significant differences found in the sensitization patterns to other allergens. In addition, no differences were found with regard to the number of allergens to which an individual patient was sensitized.

Patients with uncontrolled asthma were older (52±18 years in uncontrolled asthma and 44±17 years in controlled asthma, *p*\<0.001) and had higher serum eosinophil counts (0.64 \[IQR: 0.29--1.24\] ×10^9^/L in uncontrolled asthma and 0.41 \[IQR: 0.26--0.64\] ×10^9^/L in controlled asthma, *p*=0.006). Patients with uncontrolled asthma had lower percentage (%) predicted FEV~1~ (64.5±19.9 vs 79.7±17.7, *p*\<0.001) and FEV~1~/FVC ratios (65.8±13.3 vs 81.2±7.3, *p*\<0.001). There were no significant differences in gender, ethnicity, BMI or smoking history based on asthma control status.

Effect of *Aspergillus* and other allergens sensitization status on clinical severe asthma outcomes
---------------------------------------------------------------------------------------------------

Patients sensitized to *Aspergillus* were found to have higher steroid requirements (use of ≥2 steroid bursts in the past year): 37.5% in sensitized vs 19.8% in nonsensitized, *p*=0.048 ([Table 3](#t3-jaa-10-131){ref-type="table"}). A higher proportion of patients with *Aspergillus* sensitization had evidence of airflow obstruction (defined as FEV~1~ \<80% predicted and FEV~1~/FVC \<0.7): 54.2% vs 30.8%, *p*=0.022 ([Table 3](#t3-jaa-10-131){ref-type="table"}). Twenty (83.3%) patients with *Aspergillus* sensitization had one or more indicators of uncontrolled asthma, as compared to 89 (48.9%) patients without *Aspergillus* sensitization (*p*=0.001).

We next analyzed the impact of allergen sensitization on asthma control with adjustment for potential confounding patient characteristics of age, gender, ethnicity, BMI and smoking history as well as the presence or absence of sensitization to specific allergens ([Figure 2](#f2-jaa-10-131){ref-type="fig"}). *Aspergillus* sensitization was found to be independently associated with uncontrolled asthma (OR 6.07, 95% confidence interval \[CI\]: 1.80--20.51). In particular, *Aspergillus* sensitization was independently associated with the use of ≥2 steroid bursts in the past year (OR 3.05, 95% CI: 1.04--8.95; [Table 4](#t4-jaa-10-131){ref-type="table"}). Similar results were obtained following the addition of eosinophil counts to the multivariate analysis: *Aspergillus* sensitization was associated with uncontrolled asthma (OR 23.0, 95% CI: 2.70--195.35) and the use of ≥2 steroid bursts in the past year (OR 3.97, 95% CI: 1.17--13.52). No significant associations were found with the presence of sensitization to any other allergens ([Figure 2](#f2-jaa-10-131){ref-type="fig"}).

Baseline characteristics and outcomes of patients based on ethnicity
--------------------------------------------------------------------

Baseline characteristics and outcomes of patients based on ethnicity are presented in [Table 5](#t5-jaa-10-131){ref-type="table"}. The other 17 patients were from various other ethnicities: nine Eurasians, one Caucasian, with the rest (seven patients) consisting of Pakistanis, Bangladeshis and Sri Lankans. Chinese patients had a higher proportion of males (54.8% vs 26.5%, *p*=0.003) and had a lower BMI (kg/m^2^), compared to Malay (24.1±4.3 vs 30.0±10.0, *p*\<0.001) or Indian (24.1±4.3 vs 29.0±7.9, *p*\<0.001) patients. Chinese patients also had lower FEV1/FVC ratios compared to Indian patients (71±14 vs 79±7, *p*\<0.001). Sensitization to allergens, however, did not differ among the ethnic groups. There were also no differences in hospitalizations, admissions or use of steroids for asthma exacerbations between groups.

Discussion
==========

In our multiethnic Asian population with severe asthma, we detected a significant association between *Aspergillus* sensitization and uncontrolled asthma. Patients with *Aspergillus* sensitization had more exacerbations requiring steroid bursts, as well as evidence of airflow obstruction. No similar associations were found with sensitization to any other allergens. A high prevalence of allergen sensitization was present in our cohort, with sensitization to HDM being commonest, and most patients were sensitized to more than a single allergen.

Singapore is the world's only island city-state. It lies 1° north of the equator, has a tropical climate and stays hot and humid throughout the year. The population of \~5,600,000 consists of 74.1% Chinese, 13.4% Malay, 9.2% Indian and 3.3% other races.[@b10-jaa-10-131] Majority of asthmatics are managed by primary health care services, but more complex asthmatics have fast access to specialists in the hospitals. The Singapore General Hospital Difficult-to-treat/Severe Asthma Clinic is one such clinic and sees more than 600 patient attendances a year with majority of referrals from primary health care services or other specialists. However, despite its first world economy status and having one of the best health care systems in the world,[@b11-jaa-10-131] Singapore is an intermediate-risk country for asthma prevalence, but a high-risk country for asthma death.[@b12-jaa-10-131] The reason for this is likely to be multifactorial, including problems of adherence, health literacy and possibly, environmental factors such as allergen exposure and air pollution.

The prevalence of allergen sensitization and outcomes in a severe asthma population in Singapore (as for the rest of Asia) is not well described. Despite this, a study from North India reported high occurrences (50.9%) of *Aspergillus* sensitization in patients with severe asthma; however, this work only included patients admitted to the intensive care unit for asthma, which is not necessarily representative of the severe asthma population managed in secondary health care.[@b13-jaa-10-131] A separate study performed by the same group reported an association between *Aspergillus* sensitization and poorer lung function in asthma patients.[@b14-jaa-10-131] Again, this study was not designed to evaluate a severe asthma population, which has been characterized in our work. In our severe asthma cohort consisting of various ethnic groups (Chinese, Malay and Indian), more than one in ten were sensitized to *Aspergillus*. Our study is one of the few that describe the prevalence of *Aspergillus* sensitization in patients with severe asthma in Asia. Our reported prevalence is lower than a pooled prevalence of 28% (95% CI: 24%--34%) from a meta-analysis of 20 observational studies, none of which was performed in an Asian context.[@b15-jaa-10-131] However, these included studies were not restricted to the severe asthma population, a population among asthmatics that carries the greatest morbidity and use of health care resources. A UK-based study reported higher fungal sensitization prevalence rates of 66% among asthmatics requiring GINA step 4 or 5 medication.[@b16-jaa-10-131] Such wide discrepancies in prevalence are likely explained by differing methodological approaches. We solely used SPT for *Aspergillus* mix in our study, while the UK group employed both SPT and/or specific serum IgE to a variety of fungi and/or yeasts including *Aspergillus*, *Candida* and *Alternaria*. Despite this, prevalence of sensitization to *A. fumigatus* alone was 45% in their population, therefore highlighting highlighting the possibility of reduced sensitivity when using SPT alone, but also the likely influence of genetics and environmental difference in allergen sensitization in an Asian setting. Even in our study, differences in *Aspergillus* sensitization were found among the different ethnic groups, although not reaching statistical significance.

We also report a significant degree of sensitization to general allergens in our cohort; 78.6% of patients had sensitization to one or more allergens. This is comparable to previous studies which have collated data on severe asthma. The SARP study[@b17-jaa-10-131] and a multicenter UK ENFUMOSA[@b18-jaa-10-131] study of severe asthma reported allergen sensitization rates of 71% and 68.6%, respectively, with sensitization to HDM being the most common (71.0%). A unique observation from our data set appears to be the high prevalence of BT sensitization. While this is interesting, it is not unexpected as BT is commonly described in the tropics at low elevations that are hot and wet, with high summer rainfall.[@b19-jaa-10-131] It is also one of the predominant allergens in Singapore[@b20-jaa-10-131] and is the predominant sensitized allergen previously described in Singaporean and Malaysian asthmatic patients.[@b21-jaa-10-131],[@b22-jaa-10-131] Despite its frequency, it did not independently and significantly contribute to uncontrolled severe asthma outcomes like that demonstrated for *Aspergillus.*

Our study adds to work reporting the key association between fungal sensitization, frequent exacerbations and life-threatening asthma in a population with severe asthma as defined by medication requirements (GINA step 4 or 5).[@b23-jaa-10-131] While O'Driscoll et al[@b6-jaa-10-131] and others[@b24-jaa-10-131],[@b25-jaa-10-131] had reported the association between fungal sensitization and multiple hospital admissions, patients in their study had differing asthma severities (British Thoracic Society guidelines steps 1--4),[@b26-jaa-10-131] making conclusions difficult to draw, particularly with regard to severe asthma.

*Aspergillus* sensitization was also associated with airflow obstruction. This is consistent with prior work reporting the association of *A. fumigatus* sensitization with reduced lung function and bronchiectasis in patients with asthma.[@b7-jaa-10-131],[@b8-jaa-10-131] Sensitization to *A. fumigatus* is associated with reduced lung function in several chronic respiratory diseases, including cystic fibrosis (CF)[@b27-jaa-10-131] and chronic obstructive pulmonary disease.[@b28-jaa-10-131] The sensitization state is recognized for its clinical and prognostic importance with immunologic studies illustrating the combined use of serum IgE, *Aspergillus*-specific IgE and CD203c, a basophil surface marker in making the diagnosis of this clinical state in difficult cases.[@b29-jaa-10-131]--[@b32-jaa-10-131] There is lack of data on specifically documenting the coexistence of bronchiectasis, fixed airflow obstruction and *Aspergillus* sensitization; however, work has been performed associating bronchiectasis with fungal sensitization.[@b7-jaa-10-131],[@b8-jaa-10-131]

While it remains uncertain if the relationship between *Aspergillus* sensitization and reduced lung function is causal, the underlying pathogenesis of SAFS is believed to be in part related to triggering of the immune response from continued or repeated exposure to fungal spores.[@b33-jaa-10-131] This is similar to ABPA, where a predominant T-helper type 2 inflammatory response occurs in response to *Aspergillus*' antigens in the airways.[@b34-jaa-10-131],[@b35-jaa-10-131] Recent data from Woolnough et al further corroborate the importance of *Aspergillus* sensitization in asthma, irrespective of its severity.[@b34-jaa-10-131] They showed that IgE sensitization alone (without meeting the criteria for ABPA) to *A. fumigatus* is associated with fixed airflow obstruction and a number of radiologic abnormalities; the latter finding was also illustrated in the context of CF.[@b36-jaa-10-131],[@b37-jaa-10-131]

There is a growing body of evidence to suggest a significant degree of airway colonization in patients sensitized to *A. fumigatus*; however, importantly, colonization by this thermotolerant fungus is unrelated to its allergic manifestations.[@b38-jaa-10-131],[@b39-jaa-10-131] Importantly, \~60% of patients with moderate to severe asthma and IgE sensitization to *A. fumigatus* have positive sputum culture.[@b7-jaa-10-131] *A. fumigatus* polymerase chain reaction, a more sensitive method for its detection compared to culture alone, was positive in 70% of severe asthma with *Aspergillus* sensitization (SAAS) patients.[@b40-jaa-10-131] Subgroup analysis revealed that *A. fumigatus* polymerase chain reaction became negative following treatment with itraconazole,[@b40-jaa-10-131] a finding which was also illustrated in CF.[@b39-jaa-10-131] Taken together, it is therefore plausible that antifungal therapy may be of benefit in patients with SAFS or SAAS; however, due to different methodologies in prior studies (including patient selection, duration of antifungal treatment and end points), strong conclusions cannot be drawn.[@b41-jaa-10-131]--[@b44-jaa-10-131]

There are currently no established treatment guidelines for SAFS. However, clinicians extrapolate data from studies in ABPA, which may not be necessarily representative of this unique clinical state. There is also emerging evidence that azoles may reduce bronchial hyperresponsiveness and improve symptoms, while reducing oral steroid requirements. However, these data were derived from patients sensitized to *Trichophyton*, a less-common fungus.[@b42-jaa-10-131] Improvements in symptoms in patients with asthma and chronic rhinosinusitis with antifungal therapy have been recently described; however, their mechanisms remain unclear.[@b43-jaa-10-131] A randomized placebo-controlled study (FAST) illustrated significant improvements in Asthma Quality of Life Questionnaires at 32 weeks with itraconazole use for SAFS.[@b44-jaa-10-131] Conversely, the EVITA3 trial failed to show any effect on Asthma quality of life questionnaire (AQLQ) or asthma exacerbations at 52 weeks with voriconazole use in *A. fumigatus*-sensitized asthmatics.[@b41-jaa-10-131] Of note, however, the duration of treatment in EVITA3 was shorter than that in the FAST trial (12 vs 32 weeks, respectively), and the itraconazole used in the latter likely had stronger effects on increasing corticosteroid availability.[@b45-jaa-10-131]

Our study also highlights the clinical importance of SAFS, a phenotype of severe asthma with evidence of fungal sensitization in the absence of ABPA.[@b9-jaa-10-131] In addition, we propose that further characterization of this group into subgroups is now warranted, and here, we identify SAAS. This group of patients appears to have more frequent exacerbations and associated airflow obstruction; however, it may be underrecognized due to the absence of overt radiologic abnormalities such as bronchiectasis. SAAS patients may be potentially amenable to therapeutic interventions such as antifungal use to prevent exacerbations and achieve better disease control. Our study did not, however, include descriptions of radiologic abnormalities such as bronchiectasis and/or IgE levels, as these were not routinely performed in all patients. These would have been helpful to further characterize SAAS and ABPA in our cohort. Consequently, we were not able to reliably exclude ABPA in each case and definitively establish SAAS as a diagnosis of exclusion in this study, which is a limitation of our work. Additionally, we did not test for other fungal or yeast allergens such as *Penicillium* and *Candida* species that may have a role in cross-sensitization in our cohort.

While our findings have potential implications in identifying *Aspergillus*-sensitized severe asthma patients with poorer clinical outcomes, our study is limited by use of SPT alone as a marker of sensitization, without direct measures of allergen-specific IgE. We, therefore, have potentially underestimated the true prevalence of *Aspergillus* sensitization in our population. Opinion, however, is conflicting with regard to the utility of each of these measures to determine true sensitivity. SPT has been suggested to be more sensitive in detecting sensitization to aeroallergens in asthma,[@b46-jaa-10-131] while other important studies have reported higher sensitivity by testing for *A. fumigatus*-specific IgE levels compared to *Aspergillus* SPT alone.[@b47-jaa-10-131] A study comparing SPT and specific IgE measurements in severe asthma has suggested a degree of discordance, and both SPT and specific serum IgE are preferred for more accurate identification of fungal sensitization.[@b16-jaa-10-131]

Conclusion
==========

The prevalence of allergen sensitization in our multiethnic Asian cohort with severe asthma is high at 78.2%, and most patients were sensitized to more than a single allergen. Prevalence of *Aspergillus*-specific sensitization was 11.7%. Sensitization to *Aspergillus* but no other allergens were independently associated with poorer lung function and frequent exacerbations in severe asthma requiring additional steroid bursts. Further characterization of the SAAS phenotype, a subgroup of SAFS that could potentially be amenable to therapeutic intervention with antifungal therapy, is now warranted to reduce exacerbations and achieve better asthma control.
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![Prevalence of allergen sensitization in patients with severe asthma in an Asian cohort (N=206).\
**Abbreviations:** BT, *Blomia tropicalis*; Der F, *Dermatophagoides farinae*; Der P, *Dermatophagoides pteronyssinus*; SPT, skin prick test.](jaa-10-131Fig1){#f1-jaa-10-131}

![Multivariate analyses of allergen sensitization associated with indicators of uncontrolled asthma.\
**Note:** Age, gender, ethnicity, body mass index, smoking history (active or ex-smoker) and all other allergens were included in the multivariate analyses.\
**Abbreviations:** CI, confidence intervals; OR, odds ratio.](jaa-10-131Fig2){#f2-jaa-10-131}

###### 

Characteristics of patients with severe asthma (N=206)

  --------------------------------------------- -------------
  **Demographics**                              
  Age (years)                                   48±17
  Gender (male)                                 99 (48.1)
  Ethnicity                                     
   Chinese                                      126 (61.2)
   Malay                                        34 (16.5)
   Indian                                       29 (14.1)
   Others                                       17 (8.3)
  Body mass index (kg/m^2^)                     26.0±6.6
  Asthma control test score                     18 (15--21)
  Age of onset (years)                          22 (10--40)
  Family history of asthma                      50 (24.3)
  Allergic rhinitis                             130 (63.1)
  **Number of controllers**                     
  Two                                           91 (44.2)
  Three                                         91 (44.2)
  ≥Four                                         24 (11.6)
  **Pulmonary function test**                   
  FEV~1~, % of predicted                        71±20
  FVC, % of predicted                           76±17
  FEV~1~/FVC                                    0.73±0.13
  **Indicators of uncontrolled asthma**         
  ≥2 steroid bursts in the past year            45 (21.8)
  Hospitalization in the past year              35 (17.0)
  History of near-fatal asthma                  11 (6.3)
  FEV~1~ \<80% predicted and FEV~1~/FVC \<0.7   69 (33.5)
  Any of the above                              109 (52.9)
  --------------------------------------------- -------------

**Notes:** Values are expressed as mean ± standard deviation, median (interquartile range) and numbers (percentage). Controllers include inhaled corticosteroids, long-acting beta agonists, theophylline, leukotriene receptor antagonists, long-term steroids, omalizumab or anticholinergics.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.

###### 

Characteristics of patients with controlled and uncontrolled asthma, defined by one or more of the following: ≥2 steroid bursts in the past year, hospitalization in the past year, a history of near-fatal asthma or FEV~1~ \<80% predicted with FEV~1~/FVC \<0.7

  Patient characteristics             Controlled asthma (n=97)                                        Uncontrolled asthma (n=109)                                     *p*-value
  ----------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- -----------
  **Demographics**                                                                                                                                                    
  Age (years)                         44±17                                                           52±18                                                           \<0.001
  Gender (male)                       51 (52.6)                                                       48 (44.0)                                                       NS
  Ethnicity                                                                                                                                                           NS
   Chinese                            56 (57.7)                                                       70 (64.2)                                                       
   Malay                              19 (19.6)                                                       15 (13.8)                                                       
   Indian                             13 (13.4)                                                       16 (14.7)                                                       
   Others                             9 (9.3)                                                         8 (7.3)                                                         
  Body mass index (kg/m^2^)           26.5±6.7                                                        25.6±6.5                                                        NS
  Asthma control test score           17 (14--20)                                                     19 (15--22)                                                     NS
  Age of onset (years)                18 (6--37)                                                      25 (10--44)                                                     NS
  Active or ex-smoker                 17 (17.5)                                                       24 (22.0)                                                       NS
  Eosinophil count (10^9^/L)          0.41 (0.26--0.64)[\*](#tfn3a-jaa-10-131){ref-type="table-fn"}   0.64 (0.29--1.24)[\*](#tfn3a-jaa-10-131){ref-type="table-fn"}   0.006
  FEV~1~ (% predicted)                79.7±17.7                                                       64.5±19.9                                                       \<0.001
  FEV~1~/FVC                          81.2±7.3                                                        65.8±13.3                                                       \<0.001
  **Allergen sensitization**                                                                                                                                          
  Positive skin prick test            74 (76.3)                                                       88 (80.7)                                                       NS
   *Blomia tropicalis*                68 (70.1)                                                       77 (70.6)                                                       NS
   *Dermatophagoides pteronyssinus*   70 (72.2)                                                       76 (69.7)                                                       NS
   *Dermatophagoides farinae*         67 (69.1)                                                       76 (69.7)                                                       NS
   Dog dander                         33 (34.0)                                                       33 (30.3)                                                       NS
   Cat dander                         31 (32.0)                                                       37 (33.9)                                                       NS
   Feather                            9 (9.3)                                                         14 (12.8)                                                       NS
   Cockroach                          22 (22.7)                                                       26 (23.9)                                                       NS
   *Aspergillus*                      4 (4.1)                                                         20 (18.3)                                                       0.001
  Sensitization to ≥4 allergens       42 (43.3)                                                       54 (49.5)                                                       NS
  Number of sensitized allergens      3 (1--5)                                                        3 (2--5)                                                        NS

**Notes:** Values are expressed as mean ± standard deviation, median (interquartile range), and numbers (percentage).

Eosinophil counts available for 69 and 80 patients with controlled asthma and uncontrolled asthma, respectively.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NS, not significant.

###### 

Characteristics of patients with and without sensitization to *Aspergillus*

  Patient characteristics and outcomes          No sensitization to *Aspergillus* (n=182)                       Sensitization to *Aspergillus* (n=24)                           *p*-value
  --------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------------- -----------
  **Demographics**                                                                                                                                                              
  Age (years)                                   48±18                                                           51±18                                                           NS
  Gender (male)                                 83 (45.6)                                                       16 (66.7)                                                       0.052
  Ethnicity                                                                                                                                                                     NS
   Chinese                                      107 (58.8)                                                      19 (79.2)                                                       
   Malay                                        32 (17.6)                                                       2 (8.3)                                                         
   Indian                                       28 (15.4)                                                       1 (4.2)                                                         
   Others                                       15 (8.2)                                                        2 (8.3)                                                         
  Body mass index (kg/m^2^)                     26.1±6.7                                                        25.4±5.7                                                        NS
  Asthma control test score                     18 (15--21)                                                     20 (15--23)                                                     NS
  Active or ex-smoker                           35 (19.2)                                                       6 (25.0)                                                        NS
  Age of onset (years)                          21 (8--39)                                                      24 (10--49)                                                     NS
  Eosinophil count (×10^9^/L)                   0.50 (0.28--0.74)[\*](#tfn5a-jaa-10-131){ref-type="table-fn"}   0.58 (0.25--0.95)[\*](#tfn5a-jaa-10-131){ref-type="table-fn"}   0.006
  FEV~1~ (% predicted)                          72.3±19.6                                                       67.0±25.2                                                       NS
  FEV~1~/FVC                                    74.2±12.6                                                       64.2±15.3                                                       0.005
  **Indicators of uncontrolled asthma**                                                                                                                                         
  ≥2 Steroid bursts in the past year            36 (19.8)                                                       9 (37.5)                                                        0.048
  Hospitalization in the past year              30 (16.5)                                                       5 (20.8)                                                        NS
  History of near-fatal asthma                  10 (5.5)                                                        3 (12.5)                                                        NS
  FEV~1~ \<80% predicted and FEV~1~/FVC \<0.7   56 (30.8)                                                       13 (54.2)                                                       0.022
  Any of the above                              89 (48.9)                                                       20 (83.3)                                                       0.001

**Notes:** Values are expressed as mean ± standard deviation, median (interquartile range) and numbers (percentage).

Eosinophil counts available for 130 and 19 patients with no sensitization to *Aspergillus* and with sensitization to *Aspergillus*, respectively.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NS, not significant.

###### 

Multivariate analyses of *Aspergillus* sensitization associated with indicators of uncontrolled asthma

  Indicators of uncontrolled asthma                                                                                                                    Adjusted ORs         *p*-value
  ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -----------
  ≥2 Steroid bursts in the past year, hospitalization in the past year, history of near-fatal asthma or FEV~1~ \<80% predicted with FEV~1~/FVC \<0.7   6.07 (1.80--20.51)   0.004
  ACT \<20                                                                                                                                             0.74 (0.26--2.14)    NS
  ≥2 Steroid bursts in the past year                                                                                                                   3.05 (1.04--8.95)    0.042
  Hospitalization in the past year                                                                                                                     2.47 (0.70--8.70)    NS
  History of near-fatal asthma                                                                                                                         3.28 (0.62--17.36)   NS
  FEV~1~ \<80% predicted with FEV~1~/FVC \<0.7                                                                                                         2.59 (0.90--7.41)    0.077

**Note:** Age, gender, ethnicity, body mass index, smoking history (active or ex-smoker) and all other allergens were included in the multivariate analyses.

**Abbreviations:** ACT, asthma control test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NS, not significant; OR, odds ratio.

###### 

Characteristics of patients with severe asthma based on ethnicity

  Patient characteristics and outcomes          Chinese (n=126)                                         Malay (n=34)                                            Indian (n=29)                                           *p*-value
  --------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -----------
  **Demographics**                                                                                                                                                                                                      
  Age (years)                                   50±19                                                   42±13                                                   46±17                                                   NS
  Gender (male)                                 69 (54.8)                                               9 (26.5)                                                11 (37.9)                                               0.008
  Body mass index (kg/m^2^)                     24.1±4.3                                                30.0±10.0                                               29.0±7.9                                                \<0.001
  Age of onset (years)                          26 (10--45)                                             19 (5--39)                                              20 (8--37)                                              NS
  Active or ex-smoker                           27 (21.4)                                               8 (23.5)                                                3 (10.1)                                                NS
  Eosinophil count (10^9^/L)                    0.62±0.63[\*](#tfn9a-jaa-10-131){ref-type="table-fn"}   0.80±0.62[\*](#tfn9a-jaa-10-131){ref-type="table-fn"}   1.02±1.16[\*](#tfn9a-jaa-10-131){ref-type="table-fn"}   NS
  FEV~1~ (% predicted)                          73±22                                                   71±19                                                   68±13                                                   NS
  FEV~1~/FVC                                    71±14                                                   76±13                                                   79±7                                                    0.006
  **Allergen sensitization**                                                                                                                                                                                            
  Positive skin prick test                      101 (80.2)                                              25 (73.5)                                               21 (72.4)                                               NS
  *Blomia tropicalis*                           93 (73.8)                                               21 (61.8)                                               18 (62.1)                                               NS
  *Dermatophagoides pteronyssinus*              90 (71.4)                                               23 (67.6)                                               20 (69.0)                                               NS
  *Dermatophagoides farinae*                    92 (73.0)                                               22 (64.7)                                               15 (51.7)                                               NS
  Dog dander                                    41 (32.5)                                               9 (26.5)                                                20 (69.0)                                               NS
  Cat dander                                    43 (34.1)                                               9 (26.5)                                                8 (26.6)                                                NS
  Feather                                       11 (8.7)                                                5 (14.7)                                                7 (24.1)                                                NS
  Cockroach                                     31 (24.6)                                               9 (26.5)                                                2 (6.9)                                                 NS
  *Aspergillus*                                 19 (15.1)                                               2 (5.9)                                                 1 (3.4)                                                 NS
  Sensitization to ≥4 allergens                 64 (50.8)                                               15 (44.1)                                               8 (27.6)                                                NS
  Number of sensitized allergens                101 (80.2)                                              25 (73.5)                                               21 (72.4)                                               NS
  **Indicators of uncontrolled asthma**                                                                                                                                                                                 
  ≥2 Steroid bursts in the past year            28 (22.2)                                               7 (20.6)                                                9 (31.0)                                                NS
  Hospitalization in the past year              18 (14.3)                                               10 (29.4)                                               6 (20.7)                                                NS
  History of near-fatal asthma                  9 (7.1)                                                 1 (2.9)                                                 2 (6.9)                                                 NS
  FEV~1~ \<80% predicted and FEV~1~/FVC \<0.7   48 (38.1)                                               9 (26.5)                                                5 (17.2)                                                NS
  Any of the above                              70 (55.6)                                               15 (44.1)                                               16 (55.2)                                               NS

**Notes:** Values are expressed as mean ± standard deviation, median (interquartile range), and numbers (percentage).

Eosinophil counts available for 92, 24 and 22 patients of Chinese, Malay and Indian ethnicity, respectively.

**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; NS, not significant.

[^1]: These authors contributed equally to this work
